Newly reported from EULAR 2024: Mood Disorders Worse in RA Patients with Fibromyalgia
Newly reported from EULAR 2024: Mood Disorders Worse in RA Patients with Fibromyalgia A new study found patients with rheumatoid arthritis (RA) and fibromyalgia have greater levels of disease activity and more severe mood disorders than patients with only RA. Conversely, a correlation analysis found a positive correlation between mood disorders and disease activity in patients with RA—but not with […]
News Coverage from EULAR 2024: Filgotinib Demonstrates Early, Durable PRO Improvements in RA
News Coverage from EULAR 2024: Filgotinib Demonstrates Early, Durable PRO Improvements in RA Patients with rheumatoid arthritis (RA)receiving filgotinib had meaningful improvements in patient-reported outcomes (PROs), including pain and fatigue, which occurred early and were maintained over time, according to a post hoc analysis presented at the 2024 European Congress of Rheumatology (EULAR). “The quality of life […]
Broadcasted from EULAR 2024: Total Fish Intake in Pregnancy Could Alter Risk of Juvenile Arthritis in Offspring
Broadcasted from EULAR 2024: Total Fish Intake in Pregnancy Could Alter Risk of Juvenile Arthritis in Offspring Data from a study presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress suggests increased intake of fish, whether oily or lean, was associated with an elevated risk of offspring with juvenile idiopathic arthritis (JIA). An analysis of […]
News Coverage from EULAR 2024: FIRST Questionnaire Can Help Detect Fibromyalgia in RA Patients
News Coverage from EULAR 2024: FIRST Questionnaire Can Help Detect Fibromyalgia in RA Patients A diagnosis of fibromyalgia was associated with a negative impact on the evolution of rheumatoid arthritis (RA), leading investigators of a recent study to call for a greater emphasis on optimal screening strategies. Results of the study, which were presented at the Annual European Congress […]
Newly reported from EULAR 2024 – Brian LaMoreaux, MD: Defining and Achieving Remission in Gout with Pegloticase
Newly reported from EULAR 2024 – Brian LaMoreaux, MD: Defining and Achieving Remission in Gout with Pegloticase The MIROR program was originally developed to test the idea that concomitant methotrexate and pegloticase therapy could prevent the development of anti-drug antibodies, which often limit the treatment’s effectiveness. The results were very successful. Patients with gout receiving methotrexate had […]
Reporting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Provides Robust Improvements in Pain Among Patients with PsA
Reporting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Provides Robust Improvements in Pain Among Patients with PsA The inspiration for the Cosmos phase 3b study came from discussions that investigators, including Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology at the Janssen Pharmaceutical Companies of Johnson & Johnson, had with providers […]
Newly reported from EULAR 2024: CT-P47 Is Promising Biosimilar Candidate for Tocilizumab in RA Treatment
Newly reported from EULAR 2024: CT-P47 Is Promising Biosimilar Candidate for Tocilizumab in RA Treatment Phase 3 data presented at the Annual European Congress of Rheumatology (EULAR) 2024 found the biosimilar CT-P47 is similar in terms of efficacy, safety, and immunogenicity profile to the reference product, tocilizumab (RoActemra), for treating patients with moderate-to-severe rheumatoid arthritis (RA). “The […]
Newscasting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Demonstrates Rapid, Sustained Improvements in Severe PsA
Newscasting from EULAR 2024 – Frederic Lavie, MD, PhD: Guselkumab Demonstrates Rapid, Sustained Improvements in Severe PsA Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis (PsA), which were maintained through 2 years. In an interview with HCPLive, Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology […]
Broadcasting from EULAR 2024 – Frederic Lavie, MD, PhD: cDAPSA Demonstrates Efficacy in Monitoring Disease Activity in PsA
Broadcasting from EULAR 2024 – Frederic Lavie, MD, PhD: cDAPSA Demonstrates Efficacy in Monitoring Disease Activity in PsA Post hoc analyses of the DISCOVER-1 and DISCOVER-2 trials demonstrated the promising effects of guselkumab, a fully human interleukin (IL)-23p19-subunit inhibitor, on the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) among a cohort of patients with […]
Newscasting from EULAR 2024: Phase 3 Upadacitinib Trial Shows Promising Results for Giant Cell Arteritis Treatment
Newscasting from EULAR 2024: Phase 3 Upadacitinib Trial Shows Promising Results for Giant Cell Arteritis Treatment In an interview with HCPLive, Daniel Blockmans, MD, PhD, discussed a phase 3, randomized, placebo-controlled trial that compared 2 doses of upadacitinib versus placebo among a cohort of patients with giant cell arteritis (GCA). The findings, presented at the 2024 European […]
